1 / 32

Obstructive Airway Disease

Obstructive Airway Disease. Asthma & COPD. Rachel Ventre FY1. Spirometry/ PFT. Obstructive –  FEV1/FVC ratio Asthma COPD Bronchiectasis CF Restrictive –  FVC & FEV1. Normal or  ratio. Kyphosis/Scoliosis ILD Connective tissue diseases Infection - pneumonia. Asthma.

aerona
Download Presentation

Obstructive Airway Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Obstructive Airway Disease Asthma & COPD Rachel Ventre FY1

  2. Spirometry/ PFT • Obstructive –  FEV1/FVC ratio • Asthma • COPD • Bronchiectasis • CF • Restrictive – FVC & FEV1. Normal or  ratio. • Kyphosis/Scoliosis • ILD • Connective tissue diseases • Infection - pneumonia

  3. Asthma

  4. Definitions • Asthma • Common, chronic inflammatory airway disease, characterised by variable (diurnal) reversible airflow obstruction, airway hyper-responsiveness, bronchial inflammation and bronchospasm.

  5. Aetiology • Environment • maternal smoking during pregnancy • low air quality (pollution) • sterile environment (Hygiene hypothesis) • occupational allergens (isocyanates, epoxy resins) • Genetic • FHx of atopy. +ve twin studies.

  6. Asthma Triggers?

  7. Pathophysiology 3 main features: • Airway narrowing – bronchiole constriction • Irritation – inflammation of mucosal lining • Blockage – excess mucous production forming plugs

  8. Epidemiology • Increasing prevalence in UK • FHx of atopy • B>G3:2 in children but equal in adults • Onset – any age • Atopy? • Type I hypersensitivity to allergens • Increased tendency for T lymphocyte’s to drive IgE production on allergen exposure • Associated with Asthma, Eczema and Allergic Rhinitis (Hayfever). Runs in families.

  9. Presentation

  10. Investigations Initial Dx & assessseverity Bedside: • PEFR – with diary showing diurnal variation (>20%), morning dip • Pulse oximetry Blood: • ABG – acidotic? • Eosinophil levels, Aspergillus antibody • FBC (WCC), CRP, U&E • Blood and sputum cultures Radiology: • CXR – hyperinflation, pneumothorax, pneumonia? Special tests: • Pulmonary function tests • FEV1/FVC < 80% • Spirometry – Flow volume loop showing obstructive picture • 15% improvement post – salbutamol • Skin prick tests – allergen identification BTS uses a ‘response to therapy’ approach to asthma Dx. Chronic monitoring: PEFR – best comparison

  11. Management Conservative: • Smoking cessation • Check inhaler technique • Patient education – avoid allergens/precipitants • Emergency plan – acute exacerbations • Vaccinations – pneumococcal and influenza • Medical: BTS guidelines • Start at appropriate level for severity. Move up if necessary and step down if good control for 3 months. Rescue steroids if required in exacerbations.

  12. Stepwise Rx

  13. Acute Asthma • Acute exacerbations are common • Medical emergency • Responsible for 1000-2000 deaths/yr ? ?

  14. Management Resuscitate  ABCDE • Monitor O2 sats, ABG and PEFR • High flow 100% Oxygen (15L via non-rebreathable mask) aim sats 94-98% • Nebulisers • SABA (Salbutamol 5mg continuously then 2-4hourly) + Ipatropium Bromide 0.5mg QDS • Systemic corticosteroids • hydrocortisone 100-200mg IV then Prednisalone 40mg PO for 5/7 • Magnesium sulphate 2g over 20mins IV • Bronchodilators IV (ITU only, need cardiac monitoring) • Aminophylline or Salbutamol • Assess severity (ventilation) • Consider ITU or intubation if worsening hypoxia and PEFR despite Rx • Hypercapnia, resp acidosis, coma, respdrepression/arrest. Also if patient is tiring! • Consider patient performance status (poor  poor ITU prognosis) • Rx underlying cause – infection (ABx) or pneumothorax.

  15. COPDChronic obstructive pulmonary disease

  16. Definitions • COPD • Chronic progressive lung disorder, characterised by (mostly) irreversible airflow obstruction, FEV1 <80% predicted and FEV1/FVC ratio <70%. • Chronic bronchitis = clinical • Cough & sputum, most days, 3/12 over 2years • Chronic inflam of bronchi (medium) • Emphysema = histopathological, CXR/CT changes • Permanent destructive enlargement of airspaces • Distal to terminal bronchioles (alveolar) = bullae

  17. Aetiology • Bronchial and alveolar damage caused by environmental toxins • Cigarette smoking • Process not fully understood. Processes causing lung damage include: • Genetic • Alpha 1 antitrypsin deficiency (<1%)  Emphysema

  18. Epidemiology • Very common, many undiagnosed • More common in lower socioeconomic status (relates to smoking prevalence) • Presents in middle age or later • M>F due to smoking tendencies in past

  19. Presentation • Symptoms • Chronic productive cough • Following colds and in winter months • Increase severity and frequency over time • Sputum – can be blood stained in advanced disease • Recurrent respiratory infections • Exertional dyspnoea & reduced exercise tolerance • Regular morning cough • Wheeze

  20. Presentation • Signs:

  21. Investigations • Bedside: • PEFR – reduced • Blood: • Secondary polycythaemia • ABG - Hypoxia, normal or raised CO2 • Radiology: • CXR • Chest CT – bullae and lung volumes • Special tests: • Pulmonary function tests • Spirometry – reduced FEV1 <80% • FEV1/FVC ratio – reduced <70% (see below) • Increased lung volumes • CO gas transfer coefficient decreased when significant alveolar destruction • ECG/Echo – corpulmonale? • Sputum/blood culture

  22. CXR • Hypertranslucent lung fields • Low flat diaphragm • Bullae • Hyperinflation • >6ribs ant •  peripheral lung markings • Elongated cardiac shadow

  23. Diagnosis/Severity 4 classifications of severity of COPD:

  24. Management • Conservative: • Avoid bronchial irritation • Smoking cessation  limits FEV1 decline • Occupational allergens • Exercise • Pulmonary rehabilitation • Weight loss – correct obesity, nutritional improvement • Rx depression/social isolation – often associated

  25. Management - medical

  26. Management • Surgery: • Lung transplant in lung patients with alpha 1 antitrypsin deficiency • Bullaectomy • lung volume reduction surgery (Lobectomy – now close off the lobe using a filter)

  27. Acute COPD Mx • Rescusitation – ABCDE • 24% O2, 2L via nasal cannula or non-variable flow venture mask. • If Type II resp failure target 88-92% • Nebulisers - bronchodilators • Corticosteroids (oral/IV) • Fluids • Theophylline IV • Empirical ABx IV if infection (+/- pseudomonalcover? Tazocin, Meropenum, Gentamycin) • Consider ventilation • Consider NIV, intubation or ITU in severe cases. • Indication for NIV  persistent hypercapnia type II RF, deterioration despite 1hr best medical Rx and patient tiring.

  28. Video by Asthma UK PEFR • http://www.youtube.com/watch?v=DxBDfqPmaZU

  29. Video Asthma UKInhaler technique • MDI • http://www.youtube.com/watch?v=FqztOZLqFhE • All other inhalers • http://www.asthma.org.uk/knowledge-bank-treatment-and-medicines-using-your-inhalers

  30. LTOT • Indications: • Chronic hypoxaemia e.g COPD, ILD, Lung Ca • PaO2 <7.3kPa on air when clinically stable • PaO2 7.3-8kPa if 2* polycythaemia or pulmonary hypertension (clinical/echo) • Nocturnal hypoventilation • e.g obesity, OSA, chest wall disease • Specialist referral. Usually with CPAP or NIV. • Palliative care • For Rx of dyspnoea in terminal illness. • Assessed by respiratory physiologists • requires ABG on and off O2.

  31. Any Questions

  32. References • BTS guidelines asthma - http://www.brit-thoracic.org.uk/Portals/0/Guidelines/AsthmaGuidelines/qrg101%202011.pdf • BTS guideline COPD - http://www.nice.org.uk/nicemedia/live/13029/49399/49399.pdf • BTS guidlein LTOT - http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/Home%20Oxygen%20Service/clinical%20adultoxygenjan06.pdf • Spirometry guideline - http://www.brit-thoracic.org.uk/Portals/0/Clinical%20Information/COPD/COPD%20Consortium/spirometry_in_practice051.pdf • Asthma UK • Patient.co.uk – professional • Acutemed.co.uk • http://www.eguidelines.co.uk/eguidelinesmain/gip/vol_13/aug_10/jones_copd_aug10.php#.UlqCeBDZIa8 • Good books for finals: Clinical cases uncovered

More Related